---
title: "Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $237.79, Implies 2% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292512512.md"
description: "Analysts have raised the average 12-month price target for Charles River Laboratories International, Inc. to $237.79, implying a 2% upside from the July 10 closing price. The consensus rating remains 'Buy' among 20 covering analysts, with forecasts ranging from $180 to $265 per share."
datetime: "2026-07-13T16:20:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292512512.md)
  - [en](https://longbridge.com/en/news/292512512.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292512512.md)
generator: "portal-rs"
---

# Charles River Laboratories , Inc. Stock 12‑Month Price Target Raised to $237.79, Implies 2% Upside

-   According to estimates from 14 analysts, Charles River Laboratories International, Inc. stock's average price target has risen from $232.5 to $235.64, with forecasts ranging from $180 to $265 per share
-   Based on the Jul. 10 closing price, the updated target implies approximately 1% potential upside
-   Consensus rating remains at “Buy” across 20 covering analysts, with 15 Buys, 4 Holds and 1 Sells

Explore more price target data and ratings for Charles River Laboratories International, Inc. on the , and track all previous and future analyst recommendations for Charles River Laboratories International, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [CRL.US](https://longbridge.com/en/quote/CRL.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Insider Move at Charles River Labs: Director Cashes In on Company Stock](https://longbridge.com/en/news/296571643.md)
- [Charles River Labs director Nancy C. Andrews disposes of 573 common shares worth $163,442.52](https://longbridge.com/en/news/296533503.md)
- [Charles River and MVC to develop enterovirus vaccine](https://longbridge.com/en/news/296594849.md)
- [Charles River partners with Medigen Vaccine Biologics on NGS-backed multivalent enterovirus vaccine development](https://longbridge.com/en/news/296486690.md)
- [Charles River Labs CEVP Shannon Parisotto disposes of shares worth $1,038,051.24](https://longbridge.com/en/news/295844385.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**